NCT06416241View on ClinicalTrials.gov

Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion

PHASE4CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

December 31, 2020

Study Completion Date

March 31, 2024

Conditions
Retinal Vein OcclusionVascular Occlusive Disease
Interventions
DRUG

EYLEA 2 MG in 0.05 ML Injection

Intravitreal injection

All Listed Sponsors
lead

University of Athens

OTHER

NCT06416241 - Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion | Biotech Hunter | Biotech Hunter